133 related articles for article (PubMed ID: 22818151)
1. [Localised prostate cancer: the PREFERE trial].
Stöckle M; Bussar-Maatz R
Z Evid Fortbild Qual Gesundhwes; 2012; 106(5):333-5; discussion 335. PubMed ID: 22818151
[TBL] [Abstract][Full Text] [Related]
2. [The importance of pathology in the German prostate cancer study PREFERE].
Kristiansen G; Stöckle M; Albers P; Schmidberger H; Martus P; Wellek S; Härter M; Bussar-Maatz R; Wiegel T
Pathologe; 2013 Sep; 34(5):449-62. PubMed ID: 23963533
[TBL] [Abstract][Full Text] [Related]
3. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
Wiegel T; Albers P; Bartkowiak D; Bussar-Maatz R; Härter M; Kristiansen G; Martus P; Wellek S; Schmidberger H; Grozinger K; Renner P; Schneider F; Burmester M; Stöckle M
J Cancer Res Clin Oncol; 2021 Jan; 147(1):235-242. PubMed ID: 32886212
[TBL] [Abstract][Full Text] [Related]
4. [Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer].
Schmedders M; Janatzek S; Zimmer B
Urologe A; 2011 Aug; 50(8):938-43. PubMed ID: 21720836
[TBL] [Abstract][Full Text] [Related]
5. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
6. [Development of patient education materials for the "German Prostate Cancer Trial PREFERE"].
Sänger S; Wiegel T; Stöckle M; Härter M; Bergelt C
Z Evid Fortbild Qual Gesundhwes; 2015; 109(1):28-39. PubMed ID: 25839363
[TBL] [Abstract][Full Text] [Related]
7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
8. [PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013].
Wiegel T; Albers P; Bussar-Maatz R; Gottberg A; Härter M; Kieser M; Kristiansen G; Nettekoven G; Martus P; Schmidberger H; Wellek S; Stöckle M
Urologe A; 2013 Apr; 52(4):576-9. PubMed ID: 23571802
[TBL] [Abstract][Full Text] [Related]
9. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
10. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer.
Peschel RE; Colberg JW
Lancet Oncol; 2003 Apr; 4(4):233-41. PubMed ID: 12681267
[TBL] [Abstract][Full Text] [Related]
11. Management of early prostate cancer.
Horwich A; Parker CC; Huddart RA; Dearnaley DP
Ann Oncol; 2002; 13 Suppl 4():83-7. PubMed ID: 12401671
[No Abstract] [Full Text] [Related]
12. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
[TBL] [Abstract][Full Text] [Related]
14. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of four treatment options for low-risk prostate cancer: Preference-based randomized study for the evaluation of four treatment modalities in prostate cancer with low or "early intermediate" risk (PREFERE) - trial AP 65/11 of the AUO].
Rexer H; Bussar-Maatz R
Urologe A; 2015 May; 54(5):723-5. PubMed ID: 25802104
[No Abstract] [Full Text] [Related]
17. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
18. [PREFERE - Study on the rise].
Ohlmann CH; Stöckle M; Albers P; Schmidberger H; Härter M; Kristiansen G; Martus P; Wellek S; Bussar-Maatz R; Wiegel T
Urologe A; 2016 Mar; 55(3):313-7. PubMed ID: 26908120
[TBL] [Abstract][Full Text] [Related]
19. Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.
Gomez-Veiga F; Mariño A; Alvarez L; Rodriguez I; Fernandez C; Pertega S; Candal A
BJU Int; 2012 Feb; 109 Suppl 1():17-21. PubMed ID: 22239225
[TBL] [Abstract][Full Text] [Related]
20. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
